Kgatle, MankgopoDas, RajeshLawal, Ismaheel OpeyemiBoshomane, Tebatso M.G.Mokoala, Kgomotso M.G.Gaspar, CattleyaMbokazi, LydiaNkambule, NonhlanhlaGow, VeroniqueNdlovu, HonestMzizi, YonwabaChalwe, JosephDiphofa, JeanethMokobodi, DinahGxekwa, NobuhleZongo, LusandaMaphosa, TinasheVorster, MarizaBassa, SheynazVenkatesan, AmoudaKhanyile, RichardMunga, YunusEbenhan, ThomasZeevaart, Jan RijnSathekge, Mike Machaba2024-08-072024-08-072023-01-09Kgatle, M.; Das, R.; Lawal, I.; Boshomane, T.; Mokoala, K.; Gaspar, C.; Mbokazi, L.; Nkambule, N.; Gow, V.; Ndlovu, H.; et al. The SARS-COV-2 Seroprevalence among Oncology Patients. Journal of Clinical Medicine 2023, 12, 529. https://DOI.org/10.3390/jcm12020529.2077-0383 (online)10.3390/jcm12020529http://hdl.handle.net/2263/97498DATA AVAILABILITY STATEMENT : Data supporting reported results can be requested by email from both corresponding authors.Patients with cancer are presumed to be vulnerable to an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe clinical outcomes due to the immunocompromised state mediated by their underlying malignancies and therapy. The aim of this study was to estimate the SARS-CoV-2 seroprevalence, following second to fourth waves in solid tumour patients attending the Steve Biko Academic Hospital (SBAH) for diagnosis and treatment of cancer. We used the single-prick COVID-19 IgG/IgM Rapid Test Cassettes to detect SARS-CoV-2 IgG/IgM antibodies in 760 patients with solid tumours who were asymptomatic and who had never tested positive for coronavirus disease 2019 (COVID-19). Out of the 760 patients, 277 were male (36.4%), 483 were female (63.6%), and the mean age was 55 years (range 18–92). The estimated total seroprevalence was 33.2%. The seroprevalence status of the COVID-19 IgG/IgM antibodies rose significantly from the second wave (11.3%) to the third (67.38%) and then the fourth (69.81%) waves with roughly similar counts. A significant number of the seropositive patients were asymptomatic to COVID-19 (96%). There was a higher rate of seropositivity in cancer patients with hypertension (p < 0.05). Patients with breast, gynaecologic, and prostate cancers exhibited increased SARS-CoV-2 seropositivity. Although oncology patients may be susceptible to SARS-CoV-2 infection, our data indicate that these patients remained asymptomatic throughout various waves with an overall COVID-19 IgG/IgM antibody seropositivity of 33.16%, suggesting no risk of severe or fatal cases of COVID-19.en© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.IgG/IgM AntibodiesCancerCOVID-19 pandemicCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)South Africa (SA)SARS-CoV-2 seroprevalenceSolid tumour patientsSteve Biko Academic Hospital complex (SBAH)SDG-03: Good health and well-beingArticle